XML 109 R100.htm IDEA: XBRL DOCUMENT v3.22.1
Reportable Segment Information - Summary of Financial Information for Each Reportable Segment (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Sep. 30, 2021
Segment Reporting Information [Line Items]          
SALES $ 604 $ 509 $ 1,115 $ 977  
OPERATING INCOME (LOSS) 93 48 135 66  
DEPRECIATION EXPENSE 37 37 74 75  
AMORTIZATION EXPENSE 24 22 47 43  
EBITDA [1] 154 107 256 184  
TOTAL ASSETS 6,780   6,780   $ 6,612
Intersegment Eliminations [Member]          
Segment Reporting Information [Line Items]          
SALES [2] (20) (8) (34) (14)  
Life Sciences [Member]          
Segment Reporting Information [Line Items]          
SALES 204 185 374 355  
OPERATING INCOME (LOSS) 43 35 64 64  
DEPRECIATION EXPENSE 8 8 16 17  
AMORTIZATION EXPENSE 7 7 14 14  
EBITDA [1] 58 50 94 95  
TOTAL ASSETS 1,940   1,940   1,945
Personal Care [Member]          
Segment Reporting Information [Line Items]          
SALES 172 137 318 262  
OPERATING INCOME (LOSS) 28 19 42 33  
DEPRECIATION EXPENSE 9 9 18 19  
AMORTIZATION EXPENSE 12 10 24 19  
EBITDA [1] 49 38 84 71  
TOTAL ASSETS 1,114   1,114   1,145
Specialty Additives [Member]          
Segment Reporting Information [Line Items]          
SALES 182 158 338 305  
OPERATING INCOME (LOSS) [3] 26 19 44 21  
DEPRECIATION EXPENSE 17 16 33 33  
AMORTIZATION EXPENSE 5 5 9 9  
EBITDA [1] 48 40 86 63  
TOTAL ASSETS 1,638   1,638   1,636
Intermediates [Member]          
Segment Reporting Information [Line Items]          
SALES 66 37 119 69  
OPERATING INCOME (LOSS) 27 3 42 5  
DEPRECIATION EXPENSE 3 4 7 6  
AMORTIZATION EXPENSE       1  
EBITDA [1] 30 7 49 12  
TOTAL ASSETS 175   175   160
Unallocated and Other [Member]          
Segment Reporting Information [Line Items]          
OPERATING INCOME (LOSS) (31) (28) (57) (57)  
EBITDA [1] (31) $ (28) (57) $ (57)  
TOTAL ASSETS $ 1,913   $ 1,913   $ 1,726
[1] Excludes income (loss) from discontinued operations, other net periodic benefit income (expense) and net income (loss) on divestitures. See the Statement of Consolidated Comprehensive Income (Loss) for applicable amounts excluded.
[2] Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment transfers are accounted for at cost.
[3] Includes a capital project impairment of $9 million for the six months ended March 31, 2021 relating to a long-term capital project plan change at a plant facility.